Well, Llywydd, Adam Price is quite right that the evidence on the efficacy of the two doses is not great for Pfizer or AstaZeneca—even Pfizer, in that study, is around 30 per cent protection—which is why the booster programme is so absolutely essential. Because two doses of AstraZeneca don't protect you; two doses of AstraZeneca and a booster takes that protection up to over 70 per cent. Now, we will continue to follow the advice of the JCVI in Wales about how we prioritise calling people forward for vaccination with the booster. There is some congruence between the JCVI list of priorities and people who got AZ in the first two rounds of vaccination. So, these things have some consistency with one another. We will work our way down the age ranges, and you get to a point in people's 30s where we were actually using Pfizer rather than AZ for most people. So, I think sticking with the JCVI advice, calling people forward in order of clinical vulnerability, is the right thing to do, and to a significant, not a perfect extent, but to a significant extent that will address the issue that Adam Price has just raised with me.